TriangleDISEASE & TREATMENT SETTING
Bladder Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Bladder Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Bladder Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
14 more-specific settings
Cisplatin: advanced Bladder Cancer →KEYTRUDA: Bladder Cancer (neoadjuvant) after prior therapy →KEYTRUDA QLEX: Bladder Cancer (neoadjuvant) after prior therapy →ZUSDURI: recurrent Bladder Cancer →PADCEV EJFV: Bladder Cancer (neoadjuvant) after prior therapy →Tecentriq Hybreza: Bladder Cancer (adjuvant) after prior therapy →TECENTRIQ: Bladder Cancer (adjuvant) after prior therapy →IMFINZI: resectable Bladder Cancer (neoadjuvant) after prior therapy →Stage 0 Bladder Cancer →refractory Bladder Cancer →Stage I Bladder Cancer →Stage IV Bladder Cancer →recurrent Bladder Cancer →localized Bladder Cancer →
Study evidence for this setting
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Bupropion in Helping Adults Stop Smoking
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Acceptability of Less Harmful Alternatives to Cigarettes
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladd
Cancer in Patients With Gabapentin (GPRD)
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Indication-specific source history
2025-03-28 · durvalumab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-6b4d238ec8fdc872
- event date
- 2025-03-28
- event kind
- approval-notification
- drug or regimen
- durvalumab
- source indication text
- FDA approved durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer .
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-cdab6bdb583859b8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-12 · mitomycin intravesical solution · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-128cec353e3c27eb
- event date
- 2025-06-12
- event kind
- approval-notification
- drug or regimen
- mitomycin intravesical solution
- source indication text
- FDA approved mitomycin intravesical solution for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer .
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-4ef07a829e92c511
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-09-09 · gemcitabine intravesical system · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-d5efef1d0a2d53e8
- event date
- 2025-09-09
- event kind
- approval-notification
- drug or regimen
- gemcitabine intravesical system
- source indication text
- FDA approved gemcitabine intravesical system for adults with Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a71e076b93797c1c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-21 · pembrolizumab with enfortumab vedotin-ejfv · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-9b17d3dc0111e232
- event date
- 2025-11-21
- event kind
- approval-notification
- drug or regimen
- pembrolizumab with enfortumab vedotin-ejfv
- source indication text
- FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer who are ineligible for cisplatin.
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-645462b4c10c2fb2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-15 · atezolizumab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-4a013c9e667ffb00
- event date
- 2026-05-15
- event kind
- approval-notification
- drug or regimen
- atezolizumab
- source indication text
- FDA approved atezolizumab and atezolizumab and hyaluronidase-tqjs as adjuvant treatments for adults with muscle invasive bladder cancer after cystectomy who have circulating tumor DNA molecular residual disease as determined by an FDA-authorized test.
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-7f6ca1fc3c4ca109
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-28 · durvalumab in combination with Bacillus Calmette-Guerin · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-69942f3587f1bbbd
- event date
- 2026-05-28
- event kind
- approval-notification
- drug or regimen
- durvalumab in combination with Bacillus Calmette-Guerin
- source indication text
- FDA approved durvalumab in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer .
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-c07ece06c8530681
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-07-10 · pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- event id
- notice-860ddef787f42e83
- event date
- 2026-07-10
- event kind
- approval-notification
- drug or regimen
- pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv
- source indication text
- FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer . This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
- match phrase
- bladder cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-0403089146861ff3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- binding id
- ncit-C118816
- source collection
- ncit-concept
- source key
- C118816
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- binding id
- ncit-C4912
- source collection
- ncit-concept
- source key
- C4912
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-bladder-cancer
- binding id
- ncit-C9334
- source collection
- ncit-concept
- source key
- C9334
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice